The filing content cuts off before any financial statements or MD&A figures are presented. However, the cover page and table of contents contain substantive disclosure content (company identity, filing period, share count, registrant status classifications, exchange listing). Let me assess whether the substantive content meets the 150-word threshold. Substantive content includes: company name, state of incorporation, EIN, address, filing period (quarter ended September 30, 2026), share count as of November 6, 2026 (27,404,088 shares), exchange listing (NASDAQ:CARL), filer classifications (non-accelerated filer, smaller reporting company, emerging growth company), and the forward-looking statements section which describes the company's business (AI-enabled software solutions, interbody and fixation implants custom-designed per patient, single-use surgical instruments - the Carlsmed Technology Platform). This clearly exceeds 150 words of substantive content.

Carlsmed, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Share count: As of November 6, 2026, the registrant had 27,404,088 shares of common stock, $0.00001 par value per share, outstanding, according to the filing.
  • Exchange listing: Carlsmed common stock trades on the Nasdaq Stock Market LLC under the ticker symbol CARL, as stated on the filing's cover page.
  • Filer classifications: The company identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company under the Exchange Act definitions.
  • Extended transition period election: The registrant disclosed it has elected not to use the extended transition period for complying with new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.
  • Reporting period: The quarterly report covers the three and nine months ended September 30, 2026, with comparative periods ended September 30, 2025.
  • Technology platform: According to the filing, the company's business centers on "AI-enabled software solutions, interbody and fixation implants that we custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments" collectively described as the Carlsmed Technology Platform.

Carlsmed's Q3 2026 Quarterly Report: Filing Details and Business Description

Carlsmed, Inc. (NASDAQ:CARL), incorporated in Delaware with an IRS Employer Identification Number of 83-1081863, submitted its Form 10-Q for the quarterly period ended September 30, 2026 to the SEC. The company is headquartered at 1800 Aston Ave, Suite 100, Carlsbad, California 92008. As of November 6, 2026, the registrant reported 27,404,088 shares of common stock outstanding at a par value of $0.00001 per share.

The filing classifies Carlsmed as a non-accelerated filer, a smaller reporting company, and an emerging growth company as defined under Rule 12b-2 of the Exchange Act. The registrant confirmed it has elected not to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act, and confirmed it is not a shell company. The company stated it has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.

According to the filing, Carlsmed's core offering is the Carlsmed Technology Platform, described as consisting of "AI-enabled software solutions, interbody and fixation implants that we custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments." The filing contains forward-looking statements regarding the company's technology platform, regulatory approvals, product offerings, reimbursement strategy, surgeon adoption, manufacturing, and financial expectations, which the company characterized as subject to known and unknown risks, uncertainties, and other factors. The company stated that those forward-looking statements "represent our views as of the date on which the statements are made" and are not guarantees of future performance.

What Was Disclosed

Carlsmed filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 27,404,088 shares of common stock outstanding as of November 6, 2026, its Nasdaq listing under CARL, and its classifications as a non-accelerated filer, smaller reporting company, and emerging growth company.